CERO Therapeutics Holdings, Inc. announced on December 6, 2024, that its Board of Directors has appointed Chris Ehrlich as Chief Executive Officer. Mr. Ehrlich previously served as Interim CEO, and his permanent appointment signals leadership stability for the company.
Under his leadership, CERO Therapeutics intends to file an additional Investigational New Drug (IND) Application for CER-1236 in solid tumors during the first half of 2025. This planned expansion includes ovarian and non-small cell lung cancers, broadening the potential therapeutic application of its lead compound.
Mr. Ehrlich brings significant biotechnology industry, business development, venture capital, and investment banking experience to the role. He expressed confidence in CERO's science and team to make an impact on the market and benefit a significant patient population.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.